Ark launches Neuropad diagnostic in UK
This article was originally published in Clinica
Ark Therapeutics has released Neuropad, its test for peripheral autonomic neuropathy in the feet of diabetic patients, onto the UK market. The diagnostic also screens for diabetic foot syndrome, which can result in open foot ulcers which are both distressing for the patient and difficult to treat. Neuropad assesses the status of the sweat gland (sudomotor) response by measuring the moisture status of the foot - an abnormal sweat gland response is closely correlated with the onset of peripheral autonomic neuropathy in the feet. London, UK-based Ark licensed Neuropad from the German woundcare company Miro Verbandstoffe.